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Abstract Alterations in microRNAs expression have been
proposed to play role in endometrial cancer pathogenesis.
Dicer and Drosha are main regulators of microRNA
biogenesis and deregulation of their expression has been
indicated as a possible cause of microRNAs alterations
observed in various cancers. The objective of this study was
to investigate Dicer and Drosha genes expression in
endometrial cancer and to analyze the impact of clinico-
pathological characteristics on their expression. Fresh tissue
samples were collected from 44 patients (26 endometroid
endometrial carcinoma and 18 controls). Clinical and
pathological data were acquired from medical documenta-
tion. Dicer and Drosha genes expressions were assessed by
qRT-PCR using validated reference genes. Dicer and
Drosha expression levels were significantly lower in
endometrial cancer samples comparing to controls. Dicer
was down-regulated by the factor of 1.54 (p=0.009) and
Drosha gene mean expression value was 1.4 times lower in
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Down-regulation of Dicer significantly correlated with
decreased expression of Drosha (coefficient value 0.75).
Decreased expression of Drosha correlated with higher
histological grade and was influenced by BMI. Lower
Dicer expression was found in nulli- and uniparous females
comparing to multiparous individuals (p=0.002). Neither the
FIGO stage nor the menstrual status had significant influence
on the expression of studied genes. This study revealed for
the first time that expression alterations of main regulators of
microRNAs biogenesis are present in endometrial cancer
tissue and could be potentially responsible for altered
microRNAs profiles observed in this malignancy.
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Introduction
Endometrial cancer is the fourth most common cancer in
the female population. It was estimated that 43,470
endometrial carcinoma cases would be newly diagnosed
in 2010 in the USA [1]. Estimated number of new
endometrial cancer cases diagnosed in 2008 in Europe
equals 82,530 [2]. Deregulation of various molecules and
signaling pathways has been implicated in endometrial
oncogenesis; however, its exact pathogenesis has not been
completely elucidated [3]. Discovery of microRNAs has
brought a new insight into the pathogenesis of many
diseases including endometrial cancer [4]. MicroRNAs are
non-coding, single stranded RNAs, consisting of 22 to 26
nucleotides, which regulate gene expression on the post-
transcriptional level. Studies of the past few years have
established microRNAs as important molecules in the
pathogenesis of various solid tumors, suggesting their
possible role and utilization in cancer screening, treatment,
and prediction of outcome [4, 5]. Deregulation of micro-
RNAs expression was also observed in endometrial cancer
samples as reported by few studies [6–8]. However, the
reasons of microRNAs expression alterations observed in
this tumor type have not been elucidated so far. Deteriora-
tion of microRNA biogenesis machinery has been implied
as one possible mechanism among other suggested causes
like DNA mutations, single nucleotide polymorphism or
epigenetic changes [9–14].
Drosha and Dicer are two major components of micro-
RNA biogenesis machinery. MicroRNAs are transcribed by
polymerase II as stem-loop molecules consisting of
hundreds to thousands of nucleotides called pri-
microRNAs which are sequentially cleaved, first by
Drosha, which produces so-called pre-microRNAs, and
then by Dicer [15]. Drosha belongs to the ribonuclease III
superfamily of double-stranded RNA-specific endoribonu-
cleases, and cleaves pri-microRNAs into approximately 70
nucleotides (nt) hairpin pre-microRNAs. Interaction with
exportin-5 and Ran-GTP facilitates transport of pre- micro-
RNAs to the cytoplasm. Within the cytoplasm pre-
microRNAs are further processed by a multidomain protein
Dicer into short double-stranded molecules [15]. Apart
from Dicer and Drosha, which are main regulators of
microRNA biogenesis, the complicated microRNA machin-
ery involves other proteins including DGCR8 and Ago2,
and recently discovered co-regulators KSRP, hnRNP A1,
p53, p63, p73, which are thought to be involved in the
tissue specific microRNA processing or connected with
particular cellular conditions [16–20].
Two Dicer protein isoforms were discovered by Potenza
et al. in neuroblastoma cells, the long named Dicer1, which
was also found in various other tissues and the short one,
called t-Dicer [21]. In 2005, Irvin-Wilson and Chaudhuri
reported transcription of Dicer from an alternative promoter
as well as alternative splicing of the 5′-exons of Dicer
transcript in breast cancer cell lines, and recently, Grelier at
al. described 14 putative variants of human Dicer mRNA in
breast cancer. The three variants were found to encode a
full-length protein (variants a, b, and c), whereas two
shorter variants d and e encoded proteins of 113 and
92.7 kDa, respectively [22–24].
Alterations of Dicer and Drosha expression levels have
been found to accompany microRNA deregulations in
various malignancies including breast and ovarian cancers
[25, 26]. An importance of an intact expression of
microRNA biogenesis genes was demonstrated in Dicer
depleted mouse models, in which global decrease in
microRNAs levels was observed and was connected with
severe anatomical and functional alterations. Dicer deplet-
ed or mutant mice presented with developmental abnor-
malities and increased lethality, as well as axonal
degeneration [27, 28]. Loss of Dicer expression in mice
uterus and oviducts resulted in dramatic anatomical and
histological abnormalities [29–31].
The present study aimed to investigate Dicer and Drosha
genes expression in endometrial cancer samples by quantitive
real-time PCR using validated reference genes and to analyze
impact of clinicopathological parameters on their expression.
Material and methods
Patients
Altogether, forty-four patients were included in the study.
All patients were explained the study purpose and informed
consent was obtained from each study participant. The
Medical University of Lublin Ethical Committee has
approved the study design (decision # KE-0254/22/2009).
770 Tumor Biol. (2011) 32:769–776Twenty-six patients diagnosed with endometroid endo-
metrial cancer by endometrial biopsy performed prior to the
operation were included in the study. All patients were
scheduled for the primary surgical treatment. None of the
patients underwent any neoadiuvant therapy prior to the
operation. Upon obtaining the full pathology report, FIGO
(the International Federation of Gynecology and Obstetrics)
staging of the disease progression was performed for each
patient. Control samples were obtained from 18 females
operated due to benign gynecological diseases other than of
endometrial origin. Clinicopathological characteristics of
the patients were summarized in Table 1.
Sample collection and storage
Endometrial cancer samples were collected from histopathol-
ogy confirmed endometrial endometrioid carcinoma bulk
tumors obtained from patients undergoing hysterectomy.
Normal endometrial samples were collected from patients
undergoing hysterectomy due to benign gynecological dis-
easesotherthanofendometrialorigin.Alltissuesampleswere
collectednomorethan15minafterresectionofthe uterusand
were immediately immersed in RNAlater™ solution and
incubated in that solution for another 24 h in 4°C (Ambion,
USA). All samples were stored in −80°C until RNA isolation.
The samples were examined microscopically to ensure tumor
cellularity greater than 70%.
RNA isolation and quality control
Isolation of total RNA was performed with mirVana
Isolation Kit (Ambion) according to the manufacture's
protocol. Forty to eighty milligrams of tissue were
processed per sample. In order to reduce the amount of
the residual genomic DNA, treatment with DNAase I was
performed using the Turbo DNA-free™ Kit (Ambion)
according the manufacturer's protocol. Concentration and
purity of RNA were assessed using BioPhotometer plus
(Eppendorf, Germany) and a TrayCell (Hellma GmbH&Co,
Germany). Integrity of the RNA was evaluated by electro-
phoresis using Agilent RNA Nano kit and the Agilent
Bioanalyzer (Agilent Technologies, USA). The RIN (RNA
integrity number) values obtained for endometrial cancer
and control samples ranged between 6.6 and 9.4. The total
list of RNA samples, which includes the RIN values and
260/280 ratios of all samples, was presented in Online
Resource 1.
Reverse transcription and real-time PCR
Either 2 μg or 500 ng of total RNA was reverse transcribed
using hexamer random primers and a High Capacity cDNA
Reverse Transcritpion Kit with RNase Inhibitor (Ambion,
USA). Reverse transcription was performed in the final
volume of 20 μL. cDNA samples were tenfold diluted
before real-time PCR. Amplifications of Dicer and Drosha
were performed utilizing specific TaqMan® probes and
primers purchased from Applied Biosystems, USA (assays
IDs Hs00229023_ml and Hs01095033_m1, respectively).
Dicer isoform 1 is encoded by two transcript variants 1 and
2. Primers and probe for Dicer1 were chosen to amplify
both 1 and 2 transcript variants. In brief, each 20 μL
reaction consisted of 10 μL TaqMan® Gene Expression
Master Mix, 1 μL assay, 5 μL nuclease-free water and 4 μL
cDNA.
Real-time PCR protocol consisted of pre-incubation in
95°C for 10 min and 45 quantification cycles, each
consisting of denaturizing at 95°C for 15 s and annealing/
extension at 55°C for 1 min.
Amplification of four candidate reference genes, ACTB
(assay ID Hs99999903_m1), eIF6 (assay ID Hs001
58272_m1), RLPO (assay ID Hs99999902_m1), and HPRT
(part number 4326321E) was additionally performed in
all forty-four samples using TaqMan® probes and
primers (Applied Biosystems, USA). RT-minus, no
template control and inter-plate calibrators were included
in every run. All real-time PCR reactions were carried
out in triplicates in a Rotor Gene thermal cycler (Corbett
Research, Australia).
Efficiencies of primer/probe sets as well as a dynamic
range of the assays were determined by performing standard
Table 1 Clinicopathological characteristics of the patients
Characteristic Endometrial cancer Normal endometrium
Age (years)
* 59.6 46.25
BMI (kg/m
2)
** 30.75 27.73
Menopausal status (n)
Premenopausal 6 15
Postmenopausal 20 3
Parity (n)
Nulli- and uniparous 10 7
Multiparous 16 11
FIGO stage
1A 13 N/A
1B 8 N/A
>1 5 N/A
Myometrial invasion
<0.5 14 N/A
>0.5 12 N/A
Grade
1 14 N/A
2 11 N/A
3 1 N/A
*p<0.001;
**p=0.25
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available cDNA. Efficiencies for all assays were calculated
using the equation E=10
(−1/slope) and were between 0.9 and
0.98 (data for each assay was included in the Online
Resource 2).
Statistical analysis
Data analysis was performed using GenEx 5.2.7 software
(MultiD Analyses AB, Sweden). EIF6 and HPRT were
chosen to normalize for RNA quality and cDNA input,
basing on the Normfinder analysis of the expression of the
four candidate reference genes [32]. Normalization with
inter-plate calibrators was performed to validate for
technical variations between the runs. Mean and confidence
interval were utilized for descriptive statistics. Differences
between the groups were tested with either a student t test,
analysis of variance (one-way ANOVA with the Bonferroni
post hoc test) or Mann–Whitney tests depending on the
Kologomorov–Smirnov p value results. All tests used for
statistical analysis were two-sided. Correlations between
Dicer and Drosha expressions and clinicopathological
characteristics were assessed with Pearson test. P value of
less than 0.05 was established to denote significance in all
statistical analyses performed in the study.
Results
The mean age of patients in the endometrial cancer group
was higher comparing to control group; however, no
correlation was found between age and Dicer and Drosha
mRNA expression levels. The cancer and control groups
did not differ significantly regarding BMI (p=0.25).
Prior to statistical analysis, raw qPCR data of Dicer and
Drosha mRNA expression were normalized to two refer-
ence genes, eIF6 and HPRT. The genes were chosen from
the four candidate genes. The variability for the best
combination of genes calculated by Normfinder was
0.189, which was also confirmed by GeNorm [32, 33].
Our study revealed that both Dicer and Drosha mRNA
expressions were significantly down-regulated in endome-
trial cancer samples comparing to control group (Figs. 1
and 2). Expression of Dicer was down-regulated in cancer
group comparing to control group by the factor of 1.54 (p=
0.009). Drosha mean expression value was 1.4 times lower
in endometrial cancer group versus control group with the p
value of 0.008. Additionally, the correlation between down-
regulation of Dicer and Drosha was found with Pearson
correlation coefficient value of 0.75 (Fig. 3).
To evaluate the influence of the clinical stage on Dicer
and Drosha expression, endometrial cancer samples were
divided into two groups. One group comprised samples
staged as FIGO 1A and the other group consisted of all-
remaining samples, which were classified as FIGO stages
1B–3C. Statistical analysis did not reveal significant
differences between two groups. Similarly, no significant
differences were encountered when myometrial invasion
was taken into account.
Analysis of variance (one-way ANOVA with the Bonfer-
roni post hoc test) revealed the influence of histological grade
on Drosha expression, with the significantly higher differ-
ence detected between controls and higher-grade cancers (p=
0.038). No influence of histological grade was detected in
regards to expression of Dicer (Fig. 4).
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Fig. 1 Dicer expression in endometrial cancer samples and in the
control group (values presented in the log scale); *p=0.009
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Fig. 2 Drosha expression in endometrial cancer samples and in the
control group (values presented in the log scale); *p=0.008
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was investigated separately in the endometrial cancer and
control groups. The analysis of variance did not reveal any
influence of BMI on Dicer gene expression in endometrial
cancer group. The expression of Drosha, on the other hand,
was influenced by BMI and the post hoc tests showed
significant differences between normal weight (BMI<
25 kg/m
2, n=8) and overweight (25 kg/m
2≤BMI<30
kg/m
2, n=9) patients as well as between overweight and
obese (BMI≥30 kg/m
2, n=9) individuals (p=0.003 and p=
0.02, respectively). It is also worth to note that the
expression of both investigated genes was the lowest in
the group consisting of overweight patients, although not
significantly different in the case of Dicer. At the same time
the number of high-grade tumors did not differ significantly
between the three BMI groups. No influence of BMI on
Dicer and Drosha mRNA levels was found in the control
group.
Analysis of the influence of parity revealed significantly
lower Dicer expression in cancerous samples collected
from nulliparous and uniparous females comparing to those
obtained from multiparous individuals (p=0.002). No
influence of parity was found in control samples.
A comparison of the data in regard to the menopausal
status performed separately for cancer and control samples
did not reveal any significant differences.
Discussion
Alterations of microRNAs expression profiles were
reported in endometrial cancer by a number of studies;
however, the underlying mechanism of the observed
aberrations is still largely unresolved [6–8, 34–37]. Altered
expression of the genes involved in the microRNA
biogenesis has been implicated as a possible cause of the
differences in the microRNA profiles between normal and
cancerous tissues [14, 25, 26]. In addition, Dicer and
Drosha expressions were investigated in regard to survival
prediction in breast and ovarian cancers as well as in other
malignancies [23, 38–44]. To the best of our knowledge,
this is the first study to investigate Dicer and Drosha
expressions in endometrial cancer. Using a quantitive real-
time PCR approach and validated reference genes, we
found a decreased expression of Dicer and Drosha tran-
scripts in endometrial cancer samples in comparison to
healthy controls. In addition, the down-regulation of Dicer
significantly correlated with Drosha down-regulation.
These results are in concordance with a number of studies,
which investigated Dicer and/or Drosha gene expression
levels in ovarian and breast cancers. Merritt et al. observed
down-regulation of both Dicer and Drosha, and Pampalakis
et al. observed down-regulation of Dicer in ovarian cancer
samples [39, 45]. Moreover, in the study conducted by
Merritt et al., low expression of Dicer comprised an
independent predictor of the poor clinical outcome and
reduced disease-specific survival. The same study revealed
a correlation between Dicer and Drosha transcripts and
protein expression [39]. In contrast, Flavin et al. observed
increased Dicer mRNA and protein expression levels in
ovarian cancer samples [46]. Several studies performed in
breast cancer samples indicated down-regulation of Dicer
and/or Drosha expression in malignant comparing to
normal tissues [23, 38]. Most of those studies could not
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expression [47, 48]. The results obtained by Grelier et al.
suggested down-regulation of Dicer mRNA to be related
with greater invasiveness and metastatic spread of breast
carcinoma and to have an independent prognostic value in
metastatic disease [23].
Higher histological grade was connected with greater
invasiveness and worse prognosis in endometrial cancer
[49, 50]. Interestingly, our study revealed a correlation
between higher-grade tumors and down-regulation of
Drosha expression suggesting its possible connection with
greater invasiveness and worse prognosis of endometrial
cancer. Due to a short follow-up period, we could not
however assess the prognostic value of Drosha in our
sample group. The data revealed by our study warrants
therefore further investigation with longer observation
period and a larger group of patients.
The literature referring to the expression of Dicer
and Drosha in other tumor types is inconsistent.
Increased expression of Dicer mRNA and protein was
found in prostate and esophageal carcinomas as well as
in precursor lesions of lung adenocarcinoma, whereas
decreased levels of both Dicer and Drosha were
characteristic for high-risk neuroblastoma tumors. The
down-regulation of Dicer mRNA was reported in
hepatocellular carcinoma [41–43, 51, 52]. This may
suggest tissue- and tumor-specific alterations in micro-
RNA biogenesis genes.
Obesity comprises a well-known risk factor for
endometrial cancer [53]. Therefore we analyzed the
influence of BMI on Dicer and Drosha expression
separately in cancer samples and in normal endometrium.
We found that the expression of Drosha, but not Dicer,
was influenced by BMI and the Bonferroni post hoc test
revealed significant differences between the normal weight
and overweight patients as well as between overweight
and obese individuals. It is also worth to note that the
expression levels of both investigated genes were the
lowest in the group consisting of overweight patients,
although not significantly different in the case of Dicer.A s
the histological grade influenced Drosha expression, we
evaluated three BMI groups for the number of high-grade
tumors and found no significant difference. In the study
performed by Merritt et al., no significant associations
were present between gene expression levels and age and
tumor grade; however, low Dicer mRNA level was
correlated with advanced tumor stage [39]. Other inves-
tigators demonstrated similar associations in ovarian and
breast carcinomas [23, 38, 45]. In our study, there was no
significant association between down-regulation of Dicer
and Drosha and more advanced tumor stages; however,
there was a trend toward lower expression levels in FIGO
stages higher than 1A.
The reasons for alterations in Dicer and Drosha
expression observed in our study and other reports
published to date are largely unknown. One possible
hypothesis might be connected with the Dicer gene location
at the subtelomeric region on the chromosome 14
(14q32.13), which was found affected by allelic deletion
invarioustumors[54, 55]. Interestingly, Fujino et al. reported
a high percentage of endometrial cancers presenting loss of
heterozygosity (LOH) on 14q chromosome and defined a
minimal region of deletion for these tumors to region 14q32.
In addition, investigators observed a strong association
between 14q LOH and poor clinical outcome [56].
Biocomputational analysis performed by Pampalakis et
al. indicated DNA methylation as a possible mechanism of
Dicer down-regulation based on the presence of the strong
CpG island spanning the first exon of the gene [45, 50].
Although methylation of Dicer gene was not detected in a
lung adenocarcinoma, this possibility warrants further
investigation [40].
Recent studies suggested that regulation of Dicer
expression could appear at the posttranscriptional level
involving both mRNA and protein stage [57, 58]. In silico
algorithms revealed Dicer mRNA to bear several binding
sides for a number of various microRNAs. It was also
suggested that target sites located within the coding region,
which were recently found for let-7, could differ in
mechanism of posttranscriptional repression. Thus, micro-
RNAs by targeting various sites could potentially lead not
only to translational inhibition but also cause mRNA
instability [57, 58].
Interestingly, our search performed with Diana-
microT 3.0 and TargetScan revealed that a number of
microRNAs previously reported to be up-regulated in
endometrial cancer targeted Dicer mRNA [59, 60]. As
an example, Boren et al. reported a significant
up-regulation of miR-103, miR-107, and let-7c, which
are strongly associated with 3′UTR region of Dicer
mRNA [35]. Additionally, miR-200a and miR-141 as
well as miR-9, predicted by TargetSan, were up-regulated
in the microarray study performed by our team (data not
published, article under review).
Deregulation of p53 protein has been well established in
the pathogenesis of endometrial cancer. P53 alterations
have been mostly connected to the non-endometrioid
adenocarcinoma. Still, mutations in p53 gene were reported
in 4–32% of endometroid endometrial cancers and were
recently proposed as prognostic factors [61, 62]. P63 and
p73 protein alterations were also observed in endometrioid
endometrial tumors [61, 62]. At the same time, recent
studies suggested involvement of the p53, p63, and p73 in
regulation of microRNA processing components including
Dicer and Drosha. According to that hypothesis Dicer and
Drosha could be regulated either at the transcription step or
774 Tumor Biol. (2011) 32:769–776indirectly by p53/p63/p73-dependent microRNAs at the
posttranscriptional level [63].
In summary, our study revealed for the first time that
expression alterations of main regulators of microRNAs
biogenesis are present in endometrial cancer tissue and
could be potentially responsible for altered microRNAs
profiles observed in this malignancy. This interesting
observation warrants further studies, which would explore
correlations with protein expression as well as functional
sequel and consequences of Dicer and Drosha expression
deregulation in endometrial cancer cell lines.
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